The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Drugs & Targets

Venclexta + azacitidine receive breakthrough therapy designation from FDA for myelodysplastic syndromes

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Venclexta (venetoclax) in combination with azacitidine was granted Breakthrough Therapy Designation from FDA for the treatment of adult patients with previously untreated intermediate, high- and very high-risk myelodysplastic syndromes based on the revised International Prognostic Scoring System. 

This designation was granted based on interim results from the phase Ib M15-531 study investigating Venclexta plus azacitidine in people with previously untreated, higher-risk MDS.

This is the 38th BTD for Genentech’s portfolio of medicines, and the 11th designation for its hematology portfolio.

Venclexta is being developed by AbbVie and Genentech, a member of the Roche Group.

Table of Contents

YOU MAY BE INTERESTED IN

Clinical

Oncofertility coverage mandates expand to 21 states and DC as political momentum builds
Gaps persist as patients face harrowing decisions and huge copays

The nagging pain in Mia Sandino’s right knee set in in September 2018, and throughout her freshman year at the University of Washington, she tried to ignore it. “I was being a very naive and invincible-feeling 19-year-old,” Sandino told The Cancer Letter. “I didn’t put two and two together that this area of the knee that...

By Claire Marie Porter and Sara Willa Ernst
Guest Editorial

My introduction to, and lessons learned from, Rick Pazdur

Rick Pazdur, MD, the newly appointed director for the Center for Drug Evaluation and Research at the FDA, has been described as “greyhound thin” as a result of his dedication to cycling and lifting weights in the gym each day and, for a long time, a vegetarian diet. I first met him when he was the director of the Office of Oncology Drug Products (ODP) within CDER, in 2009.
By Mikkael A. Sekeres
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account